Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allogene Therapeutics, Inc. (Nasdaq: ALLO) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Allogene files periodic reports and current reports that describe its AlloCAR T pipeline, financial condition, and key risks.
Among the most relevant filings for ALLO are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss clinical programs such as cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma, ALLO-329 in autoimmune disease, and ALLO-316 in renal cell carcinoma. These reports also include detailed risk factor sections covering topics like gene-editing technology, reliance on licensed TALEN-based platforms, and intellectual property disputes referenced in company disclosures.
Allogene also submits numerous current reports on Form 8-K to describe material events. Recent 8-K filings have furnished quarterly financial results, outlined changes to the ALPHA3 trial’s lymphodepletion regimen following safety review, and described third-party patent litigation involving Cellectis’s TALEN technology on which Allogene relies. Other filings document matters such as annual meeting voting results and the continued listing of ALLO common stock on The Nasdaq Stock Market LLC.
On Stock Titan, investors can use AI-powered tools to review these filings, surface key points, and understand how disclosures about clinical trial design, safety findings, intellectual property, and governance may relate to ALLO stock. The filings page is a central resource for tracking Allogene’s regulatory history, financial reporting, and formal statements about its allogeneic CAR T development strategy.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported a small sale of 2,867 shares of Common Stock at $2.50 per share. The company states this transaction was executed solely to cover tax withholding obligations tied to vesting restricted stock units under its equity incentive plan.
Following the sale, Beneski directly holds 195,338 shares of Allogene Therapeutics common stock. The filing explains the sale was a mandatory “sell to cover” transaction chosen by the company’s plan and is not a discretionary trade by the executive.
Allogene Therapeutics submitted a Form 144 notice for the proposed sale of 2,867 shares of Common Stock, filed 04/01/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares reflect the vesting of a restricted stock unit award dated 03/31/2026 granted under the issuer's equity compensation plan.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Beneski reported a small open-market sale of 4,835 shares of Common Stock at a weighted average price of $2.47 per share. The shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plan and were required by a “sell to cover” election, meaning the transaction was not a discretionary trade. After this sale, Beneski directly holds 198,205 shares of Allogene common stock.
Allogene Therapeutics President and CEO David D. Chang reported an open‑market sale of 47,763 shares of common stock at $2.47 per share. According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandatory “sell to cover” feature of the company’s equity incentive plan, so this was not a discretionary trade. After the transaction, Chang directly holds 5,150,599 common shares, and additional shares are held indirectly through the RTC 2019 Trust, JEC 2019 Trust, and the Chang 2006 Family Trust.
Allogene Therapeutics filed a Form 144 reporting a proposed sale of 4,835 shares of Common Stock listed on NASDAQ. The filing shows a related vesting of a restricted stock unit award on 03/13/2026 granted under the issuer's equity compensation plan. The Form 144 entry is dated 03/16/2026.
Allogene Therapeutics reported a Form 144 notice for 47,763 shares of Common Stock related to the vesting of restricted stock units on 03/13/2026. The filing lists these shares as granted under the issuer's equity compensation plan and shows the transaction date as 03/13/2026.
Allogene Therapeutics, Inc. files its annual report as a clinical-stage company focused on off‑the‑shelf, allogeneic CAR T therapies for cancer and autoimmune disease. Its approach uses gene‑edited donor T cells and a proprietary Dagger® technology to improve persistence and limit rejection.
The company’s strategy centers on three core programs: cema‑cel for large B‑cell lymphoma in the pivotal Phase 2 ALPHA3 first‑line consolidation trial, ALLO‑316 for renal cell carcinoma with RMAT designation, and ALLO‑329 for systemic autoimmune diseases with multiple Fast Track designations. Interim ALPHA3 MRD data are planned for April 2026 and initial ALLO‑329 proof‑of‑concept data for June 2026. Allogene highlights substantial accumulated and expected future losses, heavy dependence on a few lead assets and partners, manufacturing and regulatory complexity, and significant competition from autologous CAR T and other novel therapies.
Allogene Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its allogeneic CAR T pipeline. The pivotal Phase 2 ALPHA3 trial of cema-cel in large B-cell lymphoma is underway, with an interim futility analysis focused on MRD clearance and early safety planned for April 2026.
The Phase 1 RESOLUTION trial of ALLO-329 in autoimmune disease is enrolling, with proof-of-concept data expected in June 2026. The company ended Q4 2025 with $258.3 million in cash, cash equivalents and investments, guiding that its cash runway extends into the first quarter of 2028. Full-year 2025 net loss was $190.9 million, or $0.87 per share.
Allogene Therapeutics, Inc. senior vice president and chief technical officer Benjamin Machinas Beneski reported a mandatory sale of common stock to cover taxes on vested restricted stock units. He sold 7,132 shares in a sell-to-cover transaction at a weighted average price of $2.60 per share, with individual sale prices ranging from $2.60 to $2.67. After this tax-related sale, he directly owned 203,040 shares of Allogene common stock. The filing notes this transaction was required under the company’s equity incentive plan and did not represent a discretionary trade by the executive.
Allogene Therapeutics, Inc. reported a Form 144 notice for 7,132 shares of Common Stock tied to the vesting of a restricted stock unit award on 02/28/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the market.